QLI Qilian International Holding Group Ltd

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2023

 

Commission File Number: 001-39805

 

Qilian International Holding Group Ltd

 

Jiuquan Economic and Technological Development Zone

Jiuquan City, Gansu Province, 735000

People’s Republic of China

+86-0937-2689523

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

EXPLANATORY NOTE

 

Qilian International Holding Group Limited (the “Company”) is furnishing this Form 6-K to provide its financial results for the six months ended March 31, 2023.

 

Exhibits

 

Exhibit No.		Description
99.1		Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2023

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: August 4, 2023

 

	Qilian International Holding Group Ltd
	By:	/s/ Zhangchang Xin
	Name:	Zhanchang Xin
	Title:	Chief Executive Officer

 

 

 

 

 

Exhibit 99.1

 

Financial Highlights for the Six Months Ended March 31, 2023

 

		For the Six Months Ended March 31,
		2023				2022				% Change
Revenue		$	29,163,616			$	32,086,522				-9	%
Gross profit		$	2,294,746			$	3,502,491				-34	%
Gross margin			7.9	%			10.9	%			-3	%
Income from operations		$	210,631			$	1,227,245				-83	%
Net income		$	439,380			$	249,681				76	%
Net Income attributable to Qilian International Holding Group Limited (“Qilian International”)		$	495,521			$	87,862				464	%
Basic and diluted earnings per share		$	0.01			$	0.00				464	%

 

Revenue decreased by 9% year-over-year to $29.2 million for the six months ended March 31, 2023 from $32.1 million for the same period of the prior fiscal year. The revenue demoninated in Renminbi (“RMB”) decreased by 1 million RMB (equvalent to $0.14 million U.S. dollars (“USD”), using the average conversion rate for current period) The decrease in revenue translated in USD is primarily attributable to the depreciation of RMB against USD from an average exchange rate of 1 USD = 6.3712 RMB for the six months ended March 31, 2022 to an average exchange rate of 1 USD = 6.9761 for the six months ended March 31, 2023.

 

Gross profit decreased by 34% to $2.3 million for the six months ended March 31, 2023 from $3.5 million for the same period of the prior fiscal year. Gross margins were 7.9% and 10.9% for the six months ended March 31, 2023 and 2022, respectively. The decreased gross profit was mainly due to decreased gross margin from heparin products, the sales per unit of which has decreased compared to that in the six months ended March 31, 2022.

 

Income from operations was $0.2 million for the six months ended March 31, 2023, compared to income from operations of $1.2 million for the same period of the prior fiscal year, due to the decrease of gross profit, offset by the decreased of selling, general and administrative expense of $0.2 million.

 

  

Net income was $0.4 million for the six months ended March 31, 2023, compared to the net income of $0.2 million for the same period of the prior fiscal year. The increase was mainly due to the $1.2 million increase in investment income from the change of fair value of marketable securities, offset the $1.0 million decrease in income from operations as described above.

 

Net income attributable to Qilian International was $0.5 million or earnings per share of $0.01 for the six months ended March 31, 2023, compared to net income attributable to Qilian International of less than $0.1 million or, or earnings per share of $0.00,  for the same period of the prior fiscal year. Subsidiaries with non controlling interest owners  incurred loss for the six months ended March 31, 2023 compared to income for the same period in the prior year.

 

Unaudited Financial Results for the Six months ended March 31, 2023

 

Revenue

 

For the six months ended March 31, 2023, revenue decreased by $2.9 million, or 9%, to $29.2 million from $32.1 million for the same period of the prior fiscal year.

 

For the six months ended March 31, 2023, revenue from heparin products decreased by $0.4 million or 4%. The sales price of heparin product decreased from RMB 42.8 per gram for the six month ended March 31, 2022 to RMB 38.8 per gram for the six month ended March 31, 2023. Commence from February 2023, heparin product became one of the centralized procurement medicine by the PRC government which intensified the competition of the product in the market.

 

For the six months ended March 31, 2023, revenue from oxytetracycline & licorice products increased by $0.3 million or 1.7%. This is a normal fluctuation in our oxytetracycline & licorice products line business and increased sales only accounts for less than 1% of our total sales which is related to slight sales quantity increase in the current period.

 

Cost of revenue

 

Cost of revenue decreased by $1.7 million, or 6%, to $26.9 million for the six months ended March 31, 2023 from $28.6 million for the same period of the prior fiscal year. The decrease in cost of sales is primarily attributable to the depreciation RMB against USD, from an average exchange rate of 1 USD = 6.3712 RMB for the six months ended March 31, 2022 to an average exchange rate of 1 USD = 6.9761 for the six months ended March 31, 2023. The cost of revenue denominated in RMB increased by 5.3 million RMB which is discussed in the section “Gross profit” below.

 

Gross profit

 

Gross profit decreased by $1.2 million, or 34%, to $2.3 million for the six months ended March 31, 2023 from $3.5 million for the same period of the prior fiscal year, mainly due to the decrease of gross margin of $0.9 million from heparin product and susage casing, $0.5 million from oxytetracycline & Licorice products, partially offset by the increased gross margin of $0.2 million from natural fertilizer. As a result, gross margin percentage decreased to 7.9% for the six months ended March 31, 2023 from 10.9% for the same period of the prior fiscal year.

 

 

Gross profit margin for oxytetracycline & Licorice products decreased by 1.8% for the six months ended March 31, 2023 as a result of the increase production cost due to the higher labor cost and utility cost post pandemic, compared to the same period of last year. Gross profit margin for heparin product and susage casing decreased by 6.5% for the six months ended March 31, 2023 as a result of the decreased selling price for heparin product in the current period, compared to the same period of prior year, due to intense price competition of the product in the market, as Chinese government announced centralized procurement of the medicine from beginning of 2023.

 

Gross profit margin for fertilizer increased by 29% as the Company became one of designated suppliers by Gansu government to provide organic fertilizer for certain soil improvement projects. The sales associated with these projects are $0.3 million, with a gross profit margin over 50%.

  

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses were $2.1 million for the six months ended March 31, 2023, representing an decrease of approximately $0.2 million, or 9%, from $2.3 million for six months ended March 31, 2022. The decrease was mainly attributable $0.4 million decrease of research and development expense related to developing new products in the oxytetracycline & licorice products line for six months ended March 31, 2022, offset by increase of salary and incentive bonus for our sales force for their post-pandemic sales effort for the six months ended March 31, 2023.

 

Investment income (loss)

 

Investment income was $0.2 million for the six months ended March 31, 2023, compared to investment loss of $1.0 million for the same period of the prior fiscal year. Investment income (loss) is driven by the fair value change of the investment in available-for-sale securities.

 

Net income and net income attributable to Qilian International

 

Net income was approximately $0.4 million and $0.2 million for the six months ended March 31, 2023 and 2022. After deducting non-controlling interests, net income attributable to Qilian International was approximately $0.5 million for the six months ended March 31, 2023, compared to net income attributable to Qilian International of less than $0.1 million for the same period of the prior fiscal year.

 

Earnings per share-basic and diluted

 

After deducting non-controlling interests, earnings per share attributable to the Company was $ 0.01 per basic and diluted share, for the six months ended March 31, 2023, compared to earnings per share of less than $0.01 per basic and diluted share, for the same period of the prior fiscal year.

 

Weighted average number of shares outstanding was 35,750,000 for the six months ended March 31, 2023, compared to 35,750,000 for the same period of last fiscal year.

 

 

Financial Condition

 

As of March 31, 2023, the Company had cash and cash equivalent of $8.9 million, compared to $14.3 million as of September 30, 2022. Total working capital was $17.9 million as of March 31, 2023, compared to $20.9 million as of September 30, 2022.

 

Net cash used in operating activities was $0.4 million for the six months ended March 31, 2023, compared to net cash provided by operating activities of $4.2 million for the same period last year. Cash flows from the adjustment made to reconcile net income to net cash provided by (used in) operating actitities decreased by $0.9 million mainly due to the increased unrealized investment gain from marketable securities of $1.2 million. The decrease of cash provided by operating activities was also due to a decrease of $3.9 million in cash inflows from the change in working capital, primarily driven by $1.5 million of increase in cash outflow due to increase in inventory, $1.3 million decrease in cash inflow due to increase in note receivable, $1.6 million decrease in cash inflow due to decrease in note payable, $2.2 million decrease in cash inflow due to increase in account receivable, offset by $1.2 million increase of cash inflow from the decrease of other current assets, $0.8 million decrease of cash outflow from the increase of account payable, and $1.1 million of increase in cash inflow due to the increase in advance from customers.

 

Net cash used in investing activities was $2.3 million for the six months ended March 31, 2023, compared to net cash used in investing activities $3.5 million for the same period last year. Cash used in investing activities for the six months ended March 31, 2023 includes cash used for purchase of property and equipment of $0.4 million, cash used for purchase of intangible assets of $1.9 million and cash used for purchase of non controlling interest less than $0.1 million. Cash used in investing activities for the six months ended March 31, 2022 includes cash used for purchase of property and equipment of $1.8 million and cash used for purchase of intangible assets of $1.7 million.

 

Net cash used in financing activities was $2.9 million for the six months ended March 31, 2023, compared to net cash provided by financing activities $3.1 million for the same period of last year. Cash used in financing activities for the six months ended March 31, 2023 includes cash used for repayment of bank loan and bank notes payable of $1.0 million, as well as dividend paid of $1.8 million. Cash provided by financing activities for the six months ended March 31, 2022 include cash proceeds from bank loans of $3.1 million.

 

About Qilian International Holding Group Limited

 

Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China. For more information, visit the company’s website at http://ir.qlsyy.net/.

 

Forward-Looking Statements

 

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, financial needs and the successful construction of the pig by-product processing project facility. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.

 

 

Qilian International Holding Group Limited and Subsidiaries

Condensed Consolidated Balance Sheets

 

		As of March 31				As of September 30
		2023 (Unaudited)				2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalent		$	8,879,727			$	14,319,234
Restricted cash			834,479				659,779
Accounts receivable, net			1,583,751				815,325
Bank acceptance notes receivable			3,792,801				2,585,886
Inventories, net			10,895,897				8,879,486
Advances to suppliers, net			948,069				1,215,105
Other current assets			144,575				1,559,174
TOTAL CURRENT ASSETS			27,079,299				30,033,989
Property and equipment, net			10,720,407				10,184,029
Intangible assets, net			3,679,794				1,726,928
Investment in available-for-sale securities			19,716,200				19,470,400
Long term investment			611,031				617,570
Operating lease right of use assets			75,527				86,584
Deferred tax assets			83,088				212,876
Prepayments for property and equipment			2,093,705				2,021,330
Other long term assets			174,733				172,911
TOTAL  ASSETS			64,233,784				64,526,617
CURRENT LIABILITIES:
Bank loans			-				140,578.00
Accounts payable			4,392,304				5,289,481
Advance from customers			2,484,007				556,418
Bank notes payable			598,839				1,531,649
Deferred government grants-current			81,604				121,542
Taxes payable			867,583				815,811
Operating lease liabilities, current			25,401				23,859
Accrued expenses and other payables			733,493				701,263
TOTAL CURRENT LIABILITIES			9,183,231				9,180,601
LONG TERM LIABILITIES
Operating lease liabilities, noncurrent			47,699				72,537
Deferred government grants - noncurrent			267,551				309,943
TOTAL LIABILITIES			9,498,481				9,563,081
Commitments and contingencies
EQUITY:
Ordinary Shares, $0.00166667 par value, 100,000,000 shares authorized, 35,750,000 and 35,750,000 Ordinary Shares issued and outstanding as of March 31, 2023 and September 30, 2022 , respectively			59,583				59,583
Additional paid-in capital			36,410,931				36,410,931
Statutory Reserve			3,249,316				3,118,542
Retained earnings			14,086,408				15,509,177
Accumulated other comprehensive loss			(960,401	)			(2,046,091)
Total shareholders’ equity attributable to Qilian International			52,845,837				53,052,142
Noncontrolling interests			1,889,466				1,911,394
TOTAL EQUITY			54,735,303				54,963,536
TOTAL LIABILITIES AND EQUITY			64,233,784				64,526,617

 

  

Qilian International Holding Group Limited and Subsidiaries

Condensed Consolidated Statements of Income and Comprehensive Income (unaudited)

 

		For the six months ended March 31
		2023				2022
NET REVENUE		$	29,163,616			$	32,086,522
COST OF REVENUE			26,868,870				28,584,031
GROSS PROFIT			2,294,746				3,502,491
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES			2,084,115				2,275,246
INCOME FROM OPERATIONS			210,631				1,227,245
Other income (expenses)
Interest income (expense), net			32,701				18,772
Investment income (loss)			217,593				(958,167	)
Grant income			96,259				59,225
Other income			130,450				22,759
Total Other income (expense)			477,003				(857,411	)
INCOME BEFORE INCOME TAX PROVISION			687,634				369,834
PROVISION FOR INCOME TAXES			248,254				120,153
NET INCOME			439,380				249,681
Less: net (loss) income attributable to non-controlling interest			(56,141	)			161,819
NET INCOME ATTRIBUTABLE TO QILIAN INTERNATIONAL HOLDING GROUP LIMITED		$	495,521			$	87,862
OTHER COMPREHENSIVE INCOME
Foreign currency translation adjustment			1,148,573				589,156
COMPREHENSIVE INCOME			1,587,953				838,837
Less: comprehensive income attributable to non - controlling interests			6,741				219,732
COMPREHENSIVE INCOME ATTRIBUTABLE TO QILIAN INTERNATIONAL HOLDING GROUP LIMITED			1,581,211				619,105
Earnings per common share - basic and diluted		$	0.01			$	0.00
Weighted average shares - basic and diluted			35,750,000				35,750,000

 

  

Qilian International Holding Group Limited and Subsidiaries

Condensed Consolidated Statements of Cash flows (unaudited)

 

		For the six months ended March 31
		2023				2022
Cash flows from operating activities:
Net Income		$	439,380				249,681
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Amortization of the Right-of-use assets			13,937				25,217
Depreciation and amortization			205,461				542,214
Provision (reserve) of doubtful accounts			1,281				(25,688	)
Inventory (provision) reserve			397,039				(108,861	)
Deferred tax expense			135,274				82,257
Unrealized gain (loss) from marketable securities			(245,800	)			988,800
Investment income (loss)			28,207				(30,633	)
Changes in operating assets and liabilities:
Accounts receivable			(728,868	)			1,487,728
Bank acceptance notes receivable			(1,096,994	)			224,657
Bank acceptance notes payable			-				1,657,977
Inventories			(2,069,096	)			(535,184	)
Advances to suppliers			305,403				654,668
Other current assets			1,450,828				287,351
Accounts payable			(1,069,672	)			(1,851,881	)
Advance from customers			1,877,996				712,649
Advance from customers - related parties			-				(7,795	)
Deferred government grants			(96,259	)			(136,176	)
Taxes payable			22,210				6,646
Accrued expenses and other payables			7,009				4,416
Operating lease liabilities			(26,331	)			(40,913	)
Net cash (used in) provided by operating activities			(448,995	)			4,187,130
Cash flows from investing activities:
Purchase of property and equipment			(350,271	)			(1,748,429	)
Purchase of intangible assets			(1,885,870	)			-
Prepayment for property and equipment			-				(1,689,933	)
Purchase of non controlling interest			(28,669	)
Net cash used in investing activities			(2,264,810	)			(3,438,362	)
Cash flows from financing activities:
Proceeds from bank loans			-				3,139,126
Repayment of bank loans			(143,347	)			-
Proceeds from (Repayment of) bank notes payable			(972,291	)			-
Dividend paid			(1,787,517	)			-
Net cash (used in) provided by financing activities			(2,903,155	)			3,139,126
Effect of exchange rate change on cash and cash equivalents and restricted cash			352,153				170,904
Net (decrease) increase in cash and cash equivalents and restricted cash			(5,264,807	)			4,058,798
Cash and cash equivalents and restricted cash at beginning of period			14,979,013				12,607,373
Cash and cash equivalents and restricted cash at end of period		$	9,714,206				16,666,171
Supplemental cash flow information
Cash paid for interest		$	-			$	151,456
Cash paid for income taxes		$	26,990			$	140,331
Property and equipment purchase financed by accounts payable		$				$	116,897

 

  

Qilian International Holding Group Limited and Subsidiaries
Consolidated Statements of Changes in Equity (unaudited)
		Ordinary Shares								Additional Paid-in Capital				Retained Earnings				Statutory Reserve				Accumulated Other Comprehensive Income				Shareholders'  Equity				Non-controlling Interests				Total  Equity
		Shares				Amount
Balance at September 30, 2021			35,750,000			$	59,583			$	36,390,931			$	14,693,905			$	2,857,121			$	857,066			$	54,858,606			$	1,809,852			$	56,668,458
Net income for the year															87,862												87,862				161,819				249,681
Appropriation for statutory reserve															(217,386	)			217,386								-								-
Foreign currency translation adjustment																							531,243				531,243				57,913				589,156
Balance at March 31, 2022			35,750,000			$	59,583			$	36,390,931			$	14,564,381			$	3,074,507			$	1,388,309			$	55,477,711			$	2,029,584			$	57,507,295
Balance at September 30, 2022			35,750,000				59,583				36,410,931				15,509,177				3,118,542				(2,046,091	)			53,032,142				1,911,394				54,943,536
Net income for the year															495,521												495,521				(56,141	)			439,380
Purchase of non controlling interest																															(28,669	)			(28,669	)
Appropriation for statutory reserve															(130,774	)			130,774								-								-
Dividend															(1,787,517	)											(1,787,517	)							(1,787,517	)
Foreign currency translation adjustment																							1,085,690				1,085,690				62,883				1,148,573
Balance at March 31, 2023			35,750,000			$	59,583			$	36,410,931			$	14,086,408			$	3,249,316			$	(960,401	)		$	52,845,837			$	1,889,466			$	54,735,303

 

 

---